



Proteomics International

LABORATORIES LTD

ASX Release

18 May 2021

ASX code: PIQ

Proteomics International secures major analytical services contract in pharmacokinetic testing

- **New pharmacokinetic testing contract signed with Avance Clinical**
- **Study will examine a novel lysosomal storage disorder drug as part of clinical trials**
- **The analytical services contract is Proteomics International's largest to date, valued at \$243,000**
- **The Company is actively pursuing similar high value contracts in the analytical services markets**
- **Contract links to Proteomics International's integrated business model and wider strategic vision to exploit its specialised biomarker discovery and analytical services capabilities**

Proteomics International Laboratories Ltd (Proteomics International; ASX: PIQ) has secured a major pharmacokinetic testing contract with Australia's largest clinical trial contract research organisation Avance Clinical.

The contract will see Proteomics International perform advanced pharmacokinetic testing of a novel drug for lysosomal storage disorder. It is the Company's largest single analytical services contract to date, with a value of \$243,000.

Pharmacokinetics is the study of what happens to drugs once they are inside the body, including the rate at which they are absorbed, distributed, metabolised and excreted. Australia is a leading destination for clinical trials¹ and Proteomics International offers specialist accredited testing services in this fast-growing area.

The contract with Avance Clinical is part of a Phase I clinical trial, which will examine the safety, tolerability and pharmacokinetics of the lysosomal storage drug on behalf of a US pharmaceutical company. The work will be undertaken over the next three months.

Proteomics International managing director Dr Richard Lipscombe said the Company is seeing its analytical services activity return to pre-Covid-19 levels of growth. *"Proteomics International's pharmacokinetic testing business continues to strengthen, boosting our analytical services revenue, which in turn helps offset our diagnostic R&D and commercialisation expenditure,"* he said.

Proteomics International's mission statement is to improve the quality of lives by the creation and application of innovative tools that enable the improved treatment of disease. *"Our strategy is to exploit our extensive biomarker discovery and analytical services capabilities to target new opportunities in Companion and Complementary Diagnostics (CDx), with the goal of generating valuable intellectual property,"* Dr Lipscombe said.

¹ Australian Clinical Trials Capability 2018 (Austrade)

Underpinning this ambition, the US Food & Drug Administration (FDA) is encouraging the integration of biomarkers in medical product development and approval, to support product monitoring and use in clinical practices.² Dr Lipscombe said, *“Drug developers were starting to ask for innovative biomarker-based diagnostic tests to help ensure treatments are safe and effective for patients - there was the potential for Proteomics International to create both new revenue streams and IP related to clinical trials.”*

Authorised by the Board of Proteomics International Laboratories Ltd (ASX:PIQ).

ENDS

About Avance Clinical (www.avancecro.com)

Avance Clinical is an Australian owned Contract Research Organisation that has been providing high-quality clinical research services fit for global regulatory standards to the local and international drug development industry for 20 years. Avance specialises in supporting biotech companies with their early phase clinical trials leveraging the world-class early phase clinical trials ecosystem in Australia.

Avance Clinical is able to deliver great value to biotech clients through deep experience with the ethics and regulatory process, established relationships with all of the early phase trial sites and adoption of new technologies including integrated eClinical solutions.

About Proteomics International Laboratories (PILL) (www.proteomicsinternational.com)

Proteomics International (Perth, Western Australia) is a wholly owned subsidiary and trading name of PILL (ASX: PIQ), a medical technology company at the forefront of predictive diagnostics and bio-analytical services. The Company specialises in the area of proteomics – the industrial scale study of the structure and function of proteins. It received the world’s first ISO 17025 laboratory accreditation for proteomics services, and operates from state-of-the-art facilities located on Perth’s QEII Medical Campus.

Proteomics International's business model is centred on the commercialisation of the Company's world-leading test for diabetic kidney disease, PromarkerD. The Company offsets the cash burn from R&D and product development through provision of specialist analytical services, whilst using its proprietary Promarker™ technology platform to create a pipeline of novel diagnostic tests.

For further information please contact:

Dr Richard Lipscombe
Managing Director
Proteomics International Laboratories Ltd
T: +61 8 9389 1992
E: enquiries@proteomicsinternational.com

Dirk van Dissel
Corporate Advisor & Investor Relations
Candour Advisory
T: +61 408 326 367
E: dirk@candouradvisory.com.au

Kyle Moss
Corporate Advisor
Euroz Hartleys
T: +61 8 9488 1400
E: kmoss@euroz.com

² www.fda.gov/science-research/about-science-research-fda/biomarkers-fda